Version history

{
  "session_id": "sess_SDA-2026-04-04-SDA-2026-04-04-gap-debate-20260403-222549-20260402",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "us.anthropic.claude-sonnet-4-20250514-v1:0",
  "action": "support",
  "content": "**TREM2/Microglial Druggability Assessment:**\n\n**Chemical Matter & Programs:**\n- **AL002** (Alector): TREM2 agonist antibody - Phase 2 trials\n- **Sargramostim** (GM-CSF): Microglial activation - completed Phase 2\n- **Anti-CD33 antibodies**: Multiple programs (discontinued due to toxicity)\n\n**Competitive Landscape:**\n- **Alector** (NASDAQ: ALEC): Leading TREM2 programs\n- **Denali Therapeutics**: Transport vehicle technology\n- **Genentech/Roche**: Anti-Tau programs with microglial components\n\n**Current Status:**\n- AL002 in Phase 2 for AD (results pending)\n- Multiple microglial imaging studies ongoing\n- Population-specific approaches **completely unexplored**\n\n## PRACTICAL FEASIBILITY RANKING:\n\n### **1. MOST FEASIBLE: Mitochondrial Rescue (Hypothesis 6)**\n- **Rationale**: Established drug classes, some population-specific evidence exists\n- **Immediate path**: Stratify existing NAD+/antioxidant trials by mitochondrial haplogroup\n- **Investment needed**: $15-25M for proof-of-concept study\n- **Timeline**: 3-5 years to population-stratified Phase 2\n\n### **2. MODERATE FEASIBILITY: TREM2 Modulation (Hypothesis 5)**\n- **Rationale**: Hot clinical area, but zero population data\n- **Immediate path**: Add population genetics to existing TREM2 trials\n- **Investment needed**: $30-50M for new population-stratified trial\n- **Timeline**: 5-7 years for dedicated population study\n\n### **3. LOWEST FEASIBILITY: All Others**\n- **Major barriers**: Safety concerns (estrogen), lack of chemical matter (autophagy), or insufficient mechanistic foundation\n\n## RECOMMENDED DEVELOPMENT STRATEGY:\n\n**Phase 1 (Years 1-2): $5-10M**\n- Large-scale genomic study of mitochondrial haplogroups in SEA-AD cohorts\n- Validate haplogroup-specific mitochondrial dysfunction markers\n- Screen existing mitochondrial compounds in haplogroup-stratified cell models\n\n**Phase 2 (Years 3-5): $15-25M**  \n- Population-stratified trial of lead mitochondrial compound\n- Partner with existing Asian AD cohorts/biobanks\n- Primary endpoint: population-specific biomarker responses\n\n**Success Criteria:**\n- >30% difference in treatment response between haplogroups\n- Regulatory pathway discussion with FDA/PMDA for population-specific indication\n\n**Key Risk**: All hypotheses fundamentally lack the foundational population genetics data needed for therapeutic development. Consider this a high-risk research program rather than near-term therapeutic opportunity.",
  "tokens_used": "607",
  "persona_id": "persona-domain_expert"
}